Most-Downgraded StocksMost-DowngradedNASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free ACAD Stock Alerts $14.85 -0.27 (-1.79%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$14.78▼$15.1750-Day Range$14.86▼$24.1352-Week Range$14.72▼$33.99Volume1.55 million shsAverage Volume1.80 million shsMarket Capitalization$2.45 billionP/E RatioN/ADividend YieldN/APrice Target$28.94 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ACADIA Pharmaceuticals alerts: Email Address ACADIA Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside94.9% Upside$28.94 Price TargetShort InterestBearish7.28% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.09Based on 39 Articles This WeekInsider TradingSelling Shares$1.63 M Sold Last QuarterProj. Earnings Growth76.36%From $0.55 to $0.97 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.91 out of 5 starsMedical Sector210th out of 929 stocksPharmaceutical Preparations Industry86th out of 433 stocks 4.4 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.28% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently increased by 7.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 2.3 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 39 news articles for ACADIA Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest17 people have searched for ACAD on MarketBeat in the last 30 days. This is an increase of 55% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -27% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,625,639.00 in company stock.Percentage Held by Insiders27.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 76.36% in the coming year, from $0.55 to $0.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -1,483.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -1,483.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 5.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadThe AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016.Get the full story here. About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Read More ACAD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACAD Stock News HeadlinesMay 5, 2024 | insidertrades.comJames Kihara Sells 1,326 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) StockMay 5, 2024 | insidertrades.comBrendan Teehan Sells 3,477 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) StockMay 16 at 1:08 AM | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest UpdateMay 15 at 9:03 PM | stocknews.com3 Pharma Stocks to Buy for Potential Financial FortunesMay 15 at 9:05 AM | businesswire.comAcadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett SyndromeMay 13 at 5:33 AM | americanbankingnews.comFY2026 EPS Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Boosted by Leerink PartnrsMay 13 at 4:26 AM | americanbankingnews.comACADIA Pharmaceuticals Inc. Forecasted to Earn FY2024 Earnings of $0.41 Per Share (NASDAQ:ACAD)May 13 at 2:55 AM | americanbankingnews.comQ2 2024 EPS Estimates for ACADIA Pharmaceuticals Inc. Decreased by HC Wainwright (NASDAQ:ACAD)May 12, 2024 | americanbankingnews.comHC Wainwright Cuts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $27.00May 12, 2024 | americanbankingnews.comCitigroup Trims ACADIA Pharmaceuticals (NASDAQ:ACAD) Target Price to $30.00May 12, 2024 | americanbankingnews.comRobert W. Baird Cuts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $28.00May 12, 2024 | americanbankingnews.comACADIA Pharmaceuticals' (ACAD) Buy Rating Reiterated at Needham & Company LLCMay 12, 2024 | americanbankingnews.comACADIA Pharmaceuticals' (ACAD) "Overweight" Rating Reiterated at Cantor FitzgeraldMay 12, 2024 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) PT Lowered to $21.00 at MizuhoMay 12, 2024 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) PT Lowered to $21.00 at Stifel NicolausMay 12, 2024 | americanbankingnews.comBank of America Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $22.00May 11, 2024 | markets.businessinsider.comNeutral Outlook on ACADIA Pharmaceuticals Amidst Revenue Miss and Revised Penetration ForecastsMay 11, 2024 | finance.yahoo.comResults: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 11, 2024 | americanbankingnews.comLeerink Partnrs Research Analysts Lower Earnings Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)May 10, 2024 | markets.businessinsider.comBuy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial StabilityMay 10, 2024 | finance.yahoo.comACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 10, 2024 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 1-Year Low Following Analyst DowngradeMay 9, 2024 | markets.businessinsider.comPositive Buy Rating for ACADIA Pharmaceuticals Amid Solid Market Presence and Underestimated Long-Term OpportunitiesMay 9, 2024 | markets.businessinsider.comMaintaining Buy Rating on ACADIA Pharmaceuticals Amidst Daybue’s Long-Term Growth ProspectsMay 9, 2024 | msn.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call TranscriptSee More Headlines Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/16/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees597Year FoundedN/APrice Target and Rating Average Stock Price Target$28.94 High Stock Price Target$42.00 Low Stock Price Target$19.00 Potential Upside/Downside+94.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio27.07 P/E GrowthN/ANet Income$-61,290,000.00 Net Margins-0.21% Pretax Margin1.83% Return on Equity-0.41% Return on Assets-0.24% Debt Debt-to-Equity RatioN/A Current Ratio2.04 Quick Ratio1.86 Sales & Book Value Annual Sales$726.44 million Price / Sales3.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book5.30Miscellaneous Outstanding Shares165,220,000Free Float119,785,000Market Cap$2.46 billion OptionableOptionable Beta0.42 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Stephen R. Davis J.D. (Age 63)President, CEO & Director Comp: $1.46MMr. Mark C. Schneyer (Age 49)Executive VP & CFO Comp: $701.03kMr. Brendan P. Teehan (Age 55)Executive VP, COO & Head of Commercial Comp: $724.31kMr. James K. Kihara (Age 43)VP, Chief Accounting Officer & Corporate Controller Dr. Elizabeth H.Z. Thompson Ph.D. (Age 48)Executive VP & Head of Research and Development Mr. Benir RuanoSenior Vice President of Technical Development & OperationsMr. Albert S. KildaniSenior Vice President of Investor Relations & Corporate CommunicationsMs. Jennifer J. Rhodes J.D. (Age 54)Executive VP, Chief Legal Officer & Secretary Ms. Julie FisherSenior Vice President of Marketing & Commercial StrategyMs. Holly ValdiviezSenior VP & Head of SalesMore ExecutivesKey CompetitorsDyne TherapeuticsNASDAQ:DYNRhythm PharmaceuticalsNASDAQ:RYTMJanux TherapeuticsNASDAQ:JANXIndiviorNASDAQ:INDVPTC TherapeuticsNASDAQ:PTCTView All CompetitorsInsiders & InstitutionsPrice T Rowe Associates Inc. MDSold 1,178,959 shares on 5/15/2024Ownership: 2.421%Lazard Asset Management LLCBought 17,719 shares on 5/15/2024Ownership: 0.016%Torno Capital LLCSold 86,500 shares on 5/15/2024Ownership: 0.000%Shell Asset Management Co.Bought 2,909 shares on 5/14/2024Ownership: 0.004%EntryPoint Capital LLCSold 994 shares on 5/14/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions ACAD Stock Analysis - Frequently Asked Questions Should I buy or sell ACADIA Pharmaceuticals stock right now? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACAD shares. View ACAD analyst ratings or view top-rated stocks. What is ACADIA Pharmaceuticals' stock price target for 2024? 16 equities research analysts have issued 12 month target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price targets range from $19.00 to $42.00. On average, they expect the company's stock price to reach $28.94 in the next year. This suggests a possible upside of 94.9% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. How have ACAD shares performed in 2024? ACADIA Pharmaceuticals' stock was trading at $31.31 at the beginning of 2024. Since then, ACAD stock has decreased by 52.6% and is now trading at $14.85. View the best growth stocks for 2024 here. When is ACADIA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our ACAD earnings forecast. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings data on Wednesday, May, 8th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.06. The biopharmaceutical company had revenue of $205.83 million for the quarter, compared to analysts' expectations of $208.31 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 0.41% and a negative net margin of 0.21%. The business's revenue for the quarter was up 73.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.27) EPS. What ETFs hold ACADIA Pharmaceuticals' stock? ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Invesco Biotechnology & Genome ETF (PBE) and Virtus LifeSci Biotech Products ETF (BBP).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings? ACADIA Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $930.0 million-$1.0 billion, compared to the consensus revenue estimate of $966.6 million. What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL). Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.05%), Price T Rowe Associates Inc. MD (2.42%), Jupiter Asset Management Ltd. (0.97%), Rice Hall James & Associates LLC (0.40%), Nordea Investment Management AB (0.20%) and M&G Plc (0.19%). Insiders that own company stock include Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, James Kihara, Laura Brege, Mark C Schneyer, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACAD) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
